Chemotherapy treatment patterns and clinical outcomes in patients with metastatic soft tissue sarcoma. The SArcoma treatment and Burden of Illness in North America and Europe (SABINE) study
Por:
Leahy, M, del Muro, XG, Reichardt, P, Judson, I, Staddon, A, Verweij, J, Baffoe-Bonnie, A, Jonsson, L, Musayev, A, Justo, N, Burke, T, Blay, JY, Lopez-Pousa A., SABINE Investigators
Publicada:
1 oct 2012
Resumen:
To describe chemotherapy treatment patterns and clinical outcomes in metastatic soft tissue sarcoma (mSTS) patients with favorable response to chemotherapy.
Multicenter (25) multi-country (9) retrospective chart review of mSTS patients with favorable response to chemotherapy, defined as stable disease or better following four cycles.
Two hundred and thirteen patients (58% female; mean age 54.7 years) received a mean of 2.7 lines of chemotherapy and 5.2 cycles per line. The most common first-line regimens were doxorubicin (34%) and anthracycline plus ifosfamide (30%). Favorable response was achieved by 83% to first-line and 42% and 38% in second- and third-line chemotherapy. The most common reason for chemotherapy discontinuation in lines with a favorable response was reaching a predefined number of cycles in first line (64% of 213) and disease progression in second or later lines (41% of 138). The mean time off chemotherapy was 38.0 weeks after first line, falling to 2.7-6.4 weeks in second or later lines. Median overall and progression-free survival were 23.5 (95% confidence interval 20.5-28.1) and 8.3 (7.4-9.9) months from first favorable response to chemotherapy.
mSTS patients achieving favorable response to chemotherapy have poor outcomes. Additional treatment options are needed.
Filiaciones:
Leahy, M:
Christie Hosp, Dept Med Oncol, Manchester M20 4BX, Lancs, England
del Muro, XG:
Inst Catalan Oncol, Dept Med Oncol, Barcelona, Spain
Reichardt, P:
HELIOS Klin, Dept Hematol Oncol & Palliat Care, Bad Saarow Pieskow, Germany
Judson, I:
Royal Marsden Hosp, Sarcoma Unit, London SW3 6JJ, England
Staddon, A:
Penn Oncol Hematol Associates, Philadelphia, PA USA
Verweij, J:
Erasmus Univ, Med Ctr, Dept Med Oncol, Rotterdam, Netherlands
Jonsson, L:
OptumInsight, Stockholm, Sweden
Musayev, A:
OptumInsight, Stockholm, Sweden
Justo, N:
OptumInsight, Stockholm, Sweden
Blay, JY:
Univ Lyon 1, Ctr Leon Berard, Dept Med Oncol, F-69365 Lyon, France
Lopez-Pousa A.:
Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
Bronze
|